Dr. Gordon Vanscoy, PANTHERx® CEO, to Present at the 7th Orphan Drugs & Rare Diseases Americas West Coast Congress

PANTHERx® Specialty Pharmacy’s Chairman & CEO, Dr. Gordon J. Vanscoy will be presenting a discussion on specialty pharmacy’s evolving role in rare disorders and orphan drugs at the upcoming 7th Orphan Drugs & Rare Diseases Americas West Coast Congress from June 25th – 26th in San Diego, California.

The Orphan Drugs & Rare Diseases Global Congress 2018 Americas provides a unique platform for the convergence of stakeholders in the orphan drug industry to discuss and network with top tier government, hospital, pharmaceutical, biopharmaceutical, non-profit, and orphan drug development organizations, as well as regional and local manufacturers. The agenda addresses the driving macroeconomic factors, policies and issues that will steer the development of orphan drugs globally including commercialization, policies, reimbursement, pricing and more.

Dr. Vanscoy has spent over three decades nurturing and building successful medical and pharmaceutical service businesses, including PANTHERx®, The Rare Disease Specialty Pharmacy®, and RareMed Solutions, a rare and orphan focused hub service.  Read more about Dr. Vanscoy’s achievements at https://www.pantherspecialty.com/leadership/gordon-j-vanscoy/.  Registration is still open at http://www.orphandrugsamericas.com/bookings/.

PANTHERx® Specialty Pharmacy Selected by Ultragenyx to Distribute Crysvita

PANTHERx® Specialty Pharmacy (PANTHERx®), THE Rare Disease Specialty Pharmacy®, announced that it has been selected by Ultragenyx Pharmaceutical, Inc. to distribute Crysvita™ (burosumab-twza), the very first FDA-approved therapy for children and adults with x-linked hypophosphatemia (XLH). PANTHERx® is one of a select few specialty pharmacies providing nationwide access to the medication.

Crysvita (burosumab-twza) is the first drug approved to treat adults and children ages one year and older with x-linked hypophosphatemia (XLH).  XLH causes low levels of phosphorus in the blood. It leads to impaired bone growth and development in children and adolescents and problems with bone mineralization throughout a patient’s life.  XLH is a serious disease affecting approximately 3,000 children and 12,000 adults in the United States. Most children with XLH experience bowed or bent legs, short stature, bone pain and severe dental pain. Some adults with XLH experience persistent discomfort or complications, such as joint pain, impaired mobility, tooth abscesses and hearing loss.

“The approval of Crysvita marks a turning point for patients and families who have waited what seems an eternity for a breakthrough treatment for XLH,” said Dr. Gordon Vanscoy, Chairman and CEO at PANTHERx®. “The therapy offers hope to patients, families, and caregivers and PANTHERx® is proud to support them.”

For more information about RareCareTM services for patients with XLH, contact us at 833-599-2245 or email XLHRareCare@pantherspecialty.com

About PANTHERx® Specialty Pharmacy

PANTHERx® Specialty Pharmacy, THE Rare Disease Specialty Pharmacy®, is quad-accredited and a back-to-back Zitter Health Insights Patient Choice Award winner headquartered in Pittsburgh, Pennsylvania. PANTHERx® Specialty’s mission is to transform lives by delivering medical breakthroughs, clinical excellence, and access solutions to patients afflicted with rare and devastating conditions. PANTHERx® works daily to Reinvent Specialty, Revolutionize Pharmacy, and Redefine Care®, by developing focused solutions, bold innovations, and novel clinical services associated with life-transforming therapies.